- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00571701
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized double blind placebo-controlled study,with plans to include 5 additional U.S. centers in the near future. The primary goal of this study is to determine whether celecoxib has efficacy in elimination or reduction of recurrent disease in patients with RRP. Our secondary goals are to determine whether continued celecoxib is required to maintain response, to correlate response with select patient demographics and with plasma levels of celecoxib. The study design encompasses a 30-month period, which can be divided into three segments:
Segment A: This is a 6 month run-in period in which all patients are assessed by direct laryngoscopy/bronchoscopy for disease severity, to permit growth rate stabilization and confirm accuracy of training of participating physicians. Patients will be treated by conventional surgery at three months and six months after enrollment.
Segment B: Patients begin 12 months of 400mg(adults), 100 mg (pediatric weight between 12 and 25 kg)or 200 mg (pediatric weight > 25kg) celecoxib daily or placebo treatment in addition to surgical removal of all papillomas at each 3 month interval. This segment directly tests the hypothesis that celecoxib is an efficacious treatment for moderate to severe RRP and forms the basis for the primary statistical analyses.
Segment C: The primary purpose of this segment is to determine whether gains made during celecoxib therapy are maintained after it is discontinued, or whether celecoxib will need to be taken indefinitely. This will be determined by a 12 month period on placebo after cessation of celecoxib for the early treatment group. This is not a traditional cross-over study because we expected a sustained effect therefore no efficacy studies were done in segment C. However, the placebo first group was given celecoxib so that they could gain any possible benefits equivalent to those that received the celecoxib first.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama Birmingham
-
-
California
-
San Francisco, California, United States, 94115
- UCSF Medical Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
New York
-
New Hyde Park, New York, United States, 11040
- Long Island Jewish Medical Center
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57104
- Sanford Health /USD
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Eastern Virginia Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Moderate to severe disease, defined as:
Patients who have rapid regrowth of papillomas, requiring endoscopic removal at least 3 times within the past 12 months AND A papilloma growth rate from 0.03 to 0.06 (moderate) or >0.06 (severe) at time of initial direct endoscopy OR Having tracheal and/or bronchial or pulmonary papillomatosis (severe)
- Age > 2 years
- Gender- no restriction
- Race- no restriction
Exclusion Criteria:
- Fewer than 3 surgical procedures in previous year, without tracheal disease
- Age < 2 years
- Pregnancy, trying to become pregnant, breastfeeding or not willing to comply with birth control methods if sexually active female
- Serum creatinine > 1.5 X normal
- History of documented peptic ulcer disease or gastritis persisting despite treatment
- Abnormal liver function tests, as total bilirubin >1.5 X normal and SGOT > 3 X normal
- Allergy to NSAIDs, sulfa containing drugs or symptoms of Stevens-Johnson Syndrome
- Patients with connective tissue diseases such as SLE, Raynaud's or Systemic Sclerosis
- Patients with known diabetes
- Patients on warfarin, or on loop or thiazide diuretics
- Patients with a history of cardiovascular disease, myocardial infarct or stroke
- Patients with congestive heart failure
- Patients regularly taking > 81 mg of aspirin/day
- Patients with uncontrolled hypertension
- Patients with RRP associated malignancy currently receiving chemotherapy and/or radiation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: celecoxib first, then placebo
Patients randomized to start celecoxib 6 months after enrollment.
Then cross over to placebo after 1 year.
Celecoxib dosing will be given orally 400mg once a day for adults, 200 mg once a day for pediatric patients between 12-25kg, 100mg once a day for pediatric patients < 12kg
|
Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight >25 kg
Other Names:
similar appearing capsules containing inert ingredients
|
PLACEBO_COMPARATOR: Placebo first, then celecoxib
Patients randomized to start placebo 6 months after enrollment.
One placebo capsule will be taken orally once a day.
Placebo will match appearance of active celecoxib capsules.
Cross over to 12 months of treatment with celecoxib after 1 year.
|
Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight >25 kg
Other Names:
similar appearing capsules containing inert ingredients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline
Time Frame: Baseline to 12 months
|
Change in mean growth rates during the last 3 months of the first treatment period compared to the mean values at baseline.
Endoscopy and removal of all tumor was done every 3 months.
Growth rate is calculated as the scored amount of papilloma recurrence in a 3 month period divided by the exact number of days since last endoscopy and removal of all tumor.
|
Baseline to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Patients With Positive Response to Treatment
Time Frame: Baseline to 12 months
|
Percent of patients with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline
|
Baseline to 12 months
|
Effect of Gender on Percent of Patients With Reduction in Papilloma Growth Rate Greater Than 50%.
Time Frame: Baseline to12 months
|
Percent of patients of each gender with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline
|
Baseline to12 months
|
Effect of Juvenile Versus Adult Disease Onset on Percent of Patients With Reduction in Papilloma Growth Rate Greater Than 50%.
Time Frame: Baseline to 12 months
|
Percent of juvenile versus adult onset patients with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline.
|
Baseline to 12 months
|
Effect of HPV 6 Versus HPV 11 on Percent of Patients With Reduction in Papilloma Growth Rate Greater Than 50%
Time Frame: Baseline to 12 months
|
Percent of patients with HPV 6 versus patients with HPV 11 with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline.
|
Baseline to 12 months
|
Correlation Between Mean Plasma Level of Celecoxib and Response.
Time Frame: Baseline to 12 months
|
Mean plasma levels of celecoxib over months 3-12 in first treatment period correlated with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline.
|
Baseline to 12 months
|
Maintenance of Response Following Discontinuation of Celecoxib
Time Frame: End of first treatment period (month 12) to end of second treatment period (month 24)
|
Percent of patients who responded to celecoxib with increase in papilloma growth rate of no greater than 0.01 at end of second treatment period compared to growth rate at end of first treatment period.
|
End of first treatment period (month 12) to end of second treatment period (month 24)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bettie M Steinberg, PhD, Long Island Jewish Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Infections
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- DNA Virus Infections
- Tumor Virus Infections
- Neoplasms, Squamous Cell
- Recurrence
- Respiratory Tract Infections
- Papillomavirus Infections
- Papilloma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
Other Study ID Numbers
- 1U01DC007946-01A2 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Respiratory Papillomatosis
-
National Cancer Institute (NCI)CompletedHuman Papilloma Virus | Recurrent Respiratory Papillomatosis | Laryngeal Papilloma, Recurrent | Respiratory PapillomatosisUnited States
-
Queen Sirikit National Institute of Child HealthMerck Sharp & Dohme LLCCompletedHuman Papilloma Virus | Recurrent Laryngeal PapillomatosisThailand
-
Centro de Investigación en. Enfermedades Infecciosas...UnknownRecurrent Respiratory PapillomatosisMexico
-
National Institute of Child Health, HungaryMerck Sharp & Dohme LLCUnknownRecurrent Respiratory PapillomatosisHungary
-
Nventa Biopharmaceuticals CorporationCompletedPapilloma | Recurrent Respiratory PapillomatosisUnited States
-
Imagine InstituteRecruitingJuvenile Recurrent Respiratory PapillomatosisFrance
-
Massachusetts Eye and Ear InfirmaryWithdrawnRecurrent Respiratory Papillomatosis
-
Massachusetts General HospitalCompletedRecurrent Respiratory PapillomatosisUnited States
-
National Cancer Institute (NCI)CompletedHuman Papilloma Virus | Recurrent Respiratory Papillomatosis | Laryngeal Papilloma, Recurrent | Respiratory Papillomatosis | Juvenile Laryngeal PapillomaUnited States
-
Massachusetts Eye and Ear InfirmaryRady Children's Hospital, San DiegoCompletedRecurrent Respiratory PapillomatosisUnited States
Clinical Trials on celebrex (celecoxib)
-
Dong-A ST Co., Ltd.CompletedRheumatoid ArthritisKorea, Republic of
-
University of DelawareChristiana Care Health ServicesCompleted
-
Sun Yat-sen UniversityCompletedAnkylosing SpondylitisChina
-
Seoul National University HospitalCompletedIntracerebral HemorrhageKorea, Republic of
-
POZENAstraZenecaCompletedHealthy VolunteerUnited States
-
Jonsson Comprehensive Cancer CenterCompleted
-
University of Kansas Medical CenterNational Cancer Institute (NCI)Completed
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedProstate CancerUnited States
-
Hugh McMillanFamilies of Spinal Muscular Atrophy; Gwendolyn Strong FoundationTerminatedSpinal Muscular Atrophy (SMA)Canada
-
Stony Brook UniversityBrain & Behavior Research FoundationRecruitingMajor Depressive Disorder | NeuroinflammationUnited States